Episode 373 -- Christian Focacci on Current Developments in AI and Risk Management
CareYaya: A Revolutionary Approach to Elder Care
No Password Required: CEO of HACKERverse.ai, Disruptor of Cybersecurity Sales and Most Other Things
Brooklyn District Attorney Eric Gonzalez – Innovative Approach to Safety
JONES DAY TALKS®: Women in IP – AI and Copyright Law Need-to-Knows
Hilary Preston, Vice Chair at Vinson & Elkins, Discusses Energy Innovation: Protecting Your Intellectual Property Portfolio
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 228: Designing & Manufacturing Auto-Injectors with Kimberlee Steele of SHL Medical
Innovation in Compliance: Visionary Leadership with Jackson Calame
A Thermal Storage Revolution With Nis Benn, Hyme Energy — Battery + Storage Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 225: Cancer Care Access & Treatments with Dr. Sengar of Alabama Cancer Care
Building a Business at the Intersection of Neurodata and Innovation With Rob Cooley
Approach to Responsible AI
Creating Impact Through Innovation: Brandon Kashani on Leading Mission-Driven Startups
Bridging the Gap: How CivicReach is Revolutionizing Government Customer Service
Podcast — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Podcast — UK FinReg Focus Areas in 2025: Sectoral Trends
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 218: Artificial Intelligence in Drug Development with John Van Hoy of PPD & Thermo Fisher
Driving Towards Greater Transparency and Sustainability in the EV Market with Davide Giacobbe and ScoutIt
Crafting an Effective Law Firm Generative AI Policy for Responsible Business Use: On Record PR
The Privacy Insider Podcast Episode 9: I Think, Therefore I Am: AI, Ethics, & Humanity With Dr. Michael Hemenway
May 1, 2025, marked the entry into force of most provisions of Phase I of the new Regulation (EU) 2024/2822, which forms part of the "Designs and Models Package" adopted within the European Union. This text, in addition to...more
In April 2025, we were proud to host the annual European Health & Life Sciences Symposium at the Shangri-La hotel in Paris. Attended by some 300 delegates from across the industry, participants including investors,...more
The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for certain drug products, starting with monoclonal antibodies. This shift marks a significant change...more
The U.S. Food and Drug Administration (FDA) on April 10, 2025, announced a significant policy shift aimed at reducing its reliance on animal testing for drug development and incorporating new approach methodologies (NAMs)...more
To help you stay on top of the latest news, our AI practice group has compiled a roundup of the developments we are following....more
Recorded at SCbio’s 2025 annual conference, Heather and Matthew welcome back Kimberlee Steele of SHL Medical, a global leader in medical technology design and manufacturingw. After first joining us six months ago, Kimberlee...more
What if the key to understanding and improving brain health lies in a breakthrough approach to neurodata? For Rob Cooley, founder and CEO of Nuream, unlocking the potential of brainwave data has the power to transform...more
Artificial intelligence (AI) has transformed scientific research and innovation, yet as previously discussed, the Polanyi Paradox remains a significant obstacle to using AI to generate creative solutions or breakthrough...more
Join hosts Heather, Lauren, and John as they sit down with Dr. Sengar, an accomplished oncologist from Alabama Cancer Care, a network committed to delivering quality cancer care to underserved communities. In this episode, we...more
What if the key to advancing brain health and neuroscience lies in harnessing neurodata in ways never thought possible? On today’s episode of Founder Shares, Robert S. Cooley Jr., founder and CEO of Nuream, discusses how his...more
A recent report by Precedence Research estimates the global market size for implantable medical devices will grow from USD 97.62 Billion in 2024 to USD 178.15 Billion by 2034: The rapid increase in the global market size of...more
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of our Connected With Latham podcast series,...more
A New Hope in Kidney Transplants: The Promise of Xenotransplantation - Joe’s struggle for a kidney transplant highlights a dire reality: donor shortages are leaving countless patients in limbo. Enter Dr. PK, a pioneering...more
The 2025 SCOPE Conference (Summit for Clinical Ops Executives), held last week in Orlando, FL, brought together more than 4,500 industry leaders, innovators, and experts in the clinical operations field. ...more
Since 1995, Nature Medicine has been chronicling advances in medical technology and health care. To mark the journal’s 30th anniversary, each month an issue of critical importance for the future of medicine will be...more
Medtech mergers and acquisitions (M&A) and venture capital (VC) showed signs of life in 2024, contributing to an overall optimistic outlook for the sector this year despite lingering headwinds. Strategic investments are...more
Our commercial insight and understanding of the market environment place us in a unique position to comment on M&A trends. Here are our predictions for 2025... ...more
Introduction - The year 2024 marked a pivotal time in artificial intelligence, where aspirations transformed into concrete achievements, cautions became more urgent, and the distinction between human and machine began to...more
AI is poised to revolutionize drug discovery, but uncertainty in developing protectable IP in this emerging field creates a host of potential risks for companies innovating in this space. Further complicating things: not all...more
Surgimatix, our client spotlight this month, developed what can only be called a novel solution. Surgimatix is an early-stage medical device company pioneering the first proprietary laparoscopic device that delivers...more
As a streamlined method for obtaining U.S. Food and Drug Administration ("FDA") authorization of post-market functionality, FDA issued final guidance recommending the information to include in a Predetermined Change Control...more
Recorded at NC Life Sciences Organization’s Annual Meeting, Heather and Matthew are joined by John Van Hoy, Executive Director of Data Science & Advanced Analytics at PPD, a subsidiary of Thermo Fisher. John is an innovator...more
Last week, the U.S. Food and Drug Administration (FDA) finalized guidance on the types of information that should be included in a Predetermined Change Control Plan (PCCP) as part of a marketing submission for an artificial...more